Drug Profile
Hydromorphone intranasal - Neurelis
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Aegis Therapeutics
- Developer Neurelis
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Acute pain
Highest Development Phases
- No development reported Acute pain
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Acute pain in USA (Intranasal, Spray)
- 26 Oct 2017 Chemical structure information added
- 13 Oct 2017 Hydromorphone intranasal - Aegis Therapeutics is available for licensing as of 10 Oct 2017. http://aegisthera.com/